Transdermal oxybutynin (Oxytrol) for urinary incontinence

American Family Physician

Volumn 70, Issue 12, 2004, Pages 2351-2352

  Dull, Pamela ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; N DESETHYLOXYBUTYNIN; OXYBUTYNIN; TOLTERODINE; UNCLASSIFIED DRUG;

ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DETRUSOR MUSCLE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FIRST PASS EFFECT; HUMAN; PRURITUS; REVIEW; SKIN IRRITATION; SMOOTH MUSCLE RELAXATION; SOMNOLENCE; URINE INCONTINENCE; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; CHOLINERGIC ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; MANDELIC ACIDS; PATIENT SELECTION; SAFETY; TREATMENT OUTCOME; URINARY INCONTINENCE; XEROSTOMIA;

EID: 10644278769     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Oxytrol product monograph. Watson Pharma, Inc. Accessed online November 22, 2004, at: http://pi.watsonpharm.com/prescribing_info.asp?type=pi&p=17.
2. Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5.
3. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine vesus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42.
4. Homma Y, Paick JS, Lee JG, Kawabe K. Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003;92(7):741-7.
5. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18:177-84, and Staskin DR. Methodologic shortcomings inherent in a post-hoc analysis. Curr Urol Rep. 2002;3:431-3.
6. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin. 2002;18:177-84, and Staskin DR. Methodologic shortcomings inherent in a post-hoc analysis. Curr Urol Rep. 2002;3:431-3.